Member Info for Babbler2

The Board is pleased with the execution of its strategy and expects to maintain its positive sales growth for the full year.

The Group has a strong balance sheet position with net cash of £3.54m (30 June 2018: £3.75 million), boosted by the final payment of £1.34 million against the loan note which has now been fully repaid. Deferred revenue, and hence revenue visibility, increased to £2.33m (30 June 2018: £1.08m) reflecting the long-term recurring nature of the Group's business model.

I remember posting this on TGBA but didn't buy - a couple of weeks back:

The recurring Annual Contract Value (ACV) of new contracts worldwide signed by the Group was £1.30m (2017: £0.17m) which is 136% greater than the ACV of sales achieved for the full prior financial year.

Loan note was repaid in December...

"This contract, along with other announced significant customer wins this financial year, further demonstrates the scalability of our partner centric sales and marketing strategy, a key goal for the Company.

"This strategy is particularly relevant for the public sector where we are increasingly experiencing the benefit of partners who have well-established relationships with organisations that have contact centres."

Took some at just below 25... wasn't easy :)

quiet considering... I do love a quiet low mcap share ((8.5m - almost half in cash).

How did I miss this in the news lol.

The Group has a strong balance sheet position with net cash of ££3.54m and contacts worth £4m first 6 months. No wonder its rising!

please please stop mentioning the ZOO... thanks :(

PCIP - The Group has a strong balance sheet position with net cash of £3.54m - MCap around 8m. Contract worth circa 4m in first 6 months...

Year high over 40p directors own shares at that level?
One to watch.

exactly my point... thanks for helping it ;)

likewise mate... missed out on 40% rise (well - some of that rise) after buying at 60.5 - was one of the only posters here... oh well.

some people like to average UP... as it means their investment is actually working well - as opposed to averaging DOWN - which means their investment has gone badly... ;)

Plenty of examples of shares rising from below 5p to 40p plus... don't know its possibility! ;)

*not my post - repost.

• Nuformix’s current market cap is £9.2m (2p).

• For the six months ended 30 September 2018, the company’s NAV was £4.49m (included £338,167 cash at bank).

• On the 27 November 2018, the company received £500,000 in milestone payments from NSB.

• The company is set to receive £2.5m in milestone payments from NSB in Q1 2019.

Now, less £7.49m means the market is valuing Nuformix’s highly successful cancer and fibrosis stable of drug candidates, and its substantial IP portfolio, at a paltry £1.7m!

Seriously?

Has the market totally missed this?

The company has excellent clinical data for its drug candidates, is about to move into the radar of Big Pharma, is earning significant milestone payments, is in advanced commercial discussions for its stable of drugs, and is firmly positioned for entry into Greater China and South East Asia (all multibillion dollar market opportunities), but is sporting a bargain-basement valuation of £1.7m!

Again I bark, seriously?

Frankly, if ever there was a textbook market anomaly then this is it.

Remember, the stock market is not always the perfect arbiter of value.

And yes, this spectacular value gap offers an incredible opportunity to savvy investors.

Thus, at the minimum, the company’s market cap should find a floor at £65m (15p). To this end, the risk-reward profile here is extraordinarily rare.

perhaps they did ;) Do some research....

Following the expanded agreement announced in November with NSB, Nuformix will be carrying out an additional pre-clinical study for NXP001 in parallel to its on-going clinical studies, to further validate additional differentiated product opportunities. Completion of the additional study will result in a milestone payment of £500,000 from NSB.

Total milestone payments from NSB will therefore increase from £2.5 million to £3 million, following the addition of this second pre-clinical milestone, which Nuformix expects to achieve in Q1 2019. The resulting data will support regulatory submissions in China to facilitate market approval of multiple NXP001-derived products.

lets not forget... they have stage payments coming as funding so no placing required right? £2m due soon.

rising nicely today... lets hope not another delay :@P